ArticleChina CDC weekly2025
Trends in the Incidence, Mortality and Lifetime Risks of Female Breast and Cervical Cancer - Guangdong Province, China, 2023.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retrospective study of hospitalized breast cancer patients in a Zhuhai-based hospital: analysis spanning over 20 years.Frontiers in oncology · 2026Article
- Demographic and Screening-to-Diagnosis Cascade Indicators for Risk Stratification in an Organized Cervical Cancer Screening Program: Evidence from 82,141 Women in Yunnan, China.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aims to report the epidemiological trends and provide updated estimates and lifetime risks for breast and cervical cancers among women in Guangdong province. Methods: A Bayesian age-period-cohort model was applied to project incidence and mortality rates for 2023. The adjusted for multiple primaries (AMP) method was used to calculate the lifetime risks of developing and dying from breast and cervical cancer. Joinpoint analysis was employed to describe the temporal trends. Results: The age-standardized incidence rate (ASIR) of female breast cancer increased from 2012 to 2019 in Guangdong province, with a particularly pronounced increase noted in the rural areas. The ASIR for cervical cancer among women aged over 55 increased in both urban and rural areas, whereas a declining trend was observed among women under the age of 55. The age-standardized mortality rates (ASMRs) for both breast cancer and cervical cancer demonstrated upward trends among women aged over 55, while no significant trend in ASMR was found for women under 55 years. In 2023, the estimated incidence rates of breast cancer and cervical cancer would be 50.81/10 Conclusions: Breast cancer continues to pose a significant threat to women's health in both rural and urban areas of Guangdong, whereas cancer prevention and control programs for cervical cancer have shown positive impacts among the younger population. Greater emphasis should be placed on women aged over 55 to halt the rising mortality rates of both cancers within this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.